886366-40-1

Basic information

• Product Name: ethyl 4-(p-tolyl)thiazole-2-carboxylate
• Synonyms: ethyl 4-(p-tolyl)thiazole-2-carboxylate
• CAS NO: 886366-40-1
• Molecular Weight: 301.289
• Mol File: 886366-40-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: ethyl 4-(p-tolyl)thiazole-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-(p-tolyl)thiazole-2-carboxylate(886366-40-1)
• EPA Substance Registry System: ethyl 4-(p-tolyl)thiazole-2-carboxylate(886366-40-1)

Safety Data

• Hazardous Substances Data: 886366-40-1(Hazardous Substances Data)

Upstream product

• 16982-21-1 ethyl 2-amino-2-thioxoacetate 
• 383-53-9 2-bromo-1-[4-(trifluoromethyl)phenyl]ethanone 

Downstream Products

• 939805-20-6 4-(4-trifluorophenyl)thiazole 
• 886366-98-9 4-(4-(trifluoromethyl)phenyl)thiazole-2-carboxylic acid 
• 685123-53-9 (4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)methanol 

Relevant articles and documents

Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)/PPARδ agonists as potential anti-diabetic agents

The free fatty acid receptor 1 (FFA1) and peroxisome proliferator-activated receptor δ (PPARδ) were considered as potential anti-diabetic targets, and the dual FFA1/PPARδ agonists might provide synergistic effect in insulin secretion and sensibility. Herein, we further develop dual agonists by screening 7 series of heterocycles, resulting in the discovery of compound 19 with considerable oral pharmacokinetic profile. Compound 19 exhibited a balanced potency between FFA1 and PPARδ, and high selectivity over PPARα and PPARγ. Moreover, compound 19 exerted improved glucose-lowering effects and insulin sensitivity in a dose-dependent manner, which might be attributed to its dual effects to simultaneously regulate insulin secretion and resistance. Our results extended the existing chemical space, and provided a potent tool compound 19.

Novel series of 3-amino-N-(4-aryl-1,1-dioxothian-4-yl)butanamides as potent and selective dipeptidyl peptidase IV inhibitors

A series of novel 3-amino-N-(4-aryl-1,1-dioxothian-4-yl)butanamides were investigated as dipeptidyl peptidase IV (DPP-4) inhibitors. Introduction of a 4-phenylthiazol-2-yl group showed highly potent DPP-4 inhibitory activity. Among various derivatives, (3R)-3-amino-N-(4-(4-phenylthiazol-2-yl)-tetrahydro-2H- thiopyran-4-yl)-4-(2,4,5-trifluorophenyl)butanamide 1,1-dioxide (30) reduced blood glucose excursion in an oral glucose tolerance test by oral administration.